Luye Pharma Group Ltd

LUP · F · Healthcare / Drug Manufacturers - Specialty & Generic

0.179EUR-0.01 (-3.76%)

Price History

Full chart

Market Stats

Previous Close0.186

Open0.179

Day Range0.179 – 0.179

52-Week Range0.187 – 0.39

Volume0

Market Cap818.95M

P/E (TTM)20.20

Forward P/E18.35

EPS0.01

Dividend Yield0.00%

Beta0.87

50-Day Avg0.2143

200-Day Avg0.2535

About

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People's Republic of China, the United States, Europe, and internationally. The company offers Lipusu, for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema and edema caused by trauma or surgery, and for treatment of venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes mellitus; Seroquel, Seroquel XR, Erzofri; and Rivastigmine Multi-Day Transdermal, Rotigotine transdermal, Fentanyl, and Buprenorphine patches. In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Boyoubei, a denosumab injection for the treatment of postmenopausal women with osteoporosis; and Boyouping, a dulaglutide injection for glycemic control in adults. Further, it offers Oukai; Meibirui; Jinyouping; and other products. The company distributes and sells pharmaceutical drugs; develops, manufactures, and commercialises of biologics; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Company Details

SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
CEOMr. Dian Bo Liu
Employees5.22K
HeadquartersNo. 15 Chuang Ye Road, Yantai, China, 264003, Germany
Websitehttps://www.luye.cn

Leadership

Mr. Dian Bo LiuCo-Founder, Executive Chairman, CEO and Head of Corporate Directions & Strategies · b. 1966
Mr. Rong Bing YangCo-Founder & Vice Executive Chairman · b. 1966
Mr. Hui Xian YuanCo-Founder & Executive Director · b. 1959
Ms. Yuan Yuan ZhuExecutive Director · b. 1981
Mr. Yuan Chong LiuChief Financial Officer · b. 1964
Ms. Mei Yi Lee ACIS, ACS, FCIS, FCSCompany Secretary · b. 1968

Financials

Income Statement

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Revenue	2.92B	3.81B	5.17B	6.36B	5.54B	5.20B	5.98B	6.14B	6.06B	6.31B
Growth (%)	-	+30.74%	+35.61%	+22.89%	-12.87%	-6.13%	+15.03%	+2.70%	-1.33%	+4.07%
Cost of Revenue	535.05M	851.48M	1.12B	1.48B	1.55B	1.80B	1.84B	1.94B	2.02B	2.15B
Gross Profit	2.38B	2.96B	4.05B	4.88B	3.99B	3.40B	4.14B	4.20B	4.04B	4.16B
Gross Margin	81.66%	77.68%	78.27%	76.74%	72.04%	65.32%	69.22%	68.44%	66.72%	65.99%
Operating Expense	1.47B	1.87B	2.53B	3.02B	2.78B	3.11B	3.19B	3.18B	2.75B	2.91B
Operating Income	914.71M	1.09B	1.52B	1.86B	1.22B	282.81M	953.88M	1.03B	1.29B	1.26B
Operating Margin	31.35%	28.59%	29.32%	29.25%	21.94%	5.44%	15.95%	16.75%	21.30%	19.90%
EBITDA	-	1.42B	1.96B	2.49B	1.37B	324.90M	1.81B	2.08B	2.19B	2.47B
EBITDA Margin	-	37.13%	37.91%	39.14%	24.66%	6.25%	30.31%	33.82%	36.16%	39.17%
Net Income	891.54M	981.37M	1.30B	1.47B	706.59M	-134.39M	604.81M	532.61M	471.89M	618.75M
Net Income Margin	30.56%	25.73%	25.19%	23.10%	12.76%	-2.58%	10.11%	8.67%	7.79%	9.81%
R&D	193.66M	288.70M	491.16M	579.46M	789.87M	683.16M	857.34M	586.16M	498.59M	413.92M
R&D as % of Total Revenue	6.64%	7.57%	9.49%	9.11%	14.26%	13.14%	14.33%	9.54%	8.23%	6.56%
Interest Expense	0	0	170.57M	274.61M	424.00M	399.46M	471.75M	675.45M	561.78M	686.60M
Interest Expense % of Total Revenue	0.00%	0.00%	3.30%	4.32%	7.65%	7.68%	7.89%	11.00%	9.27%	10.88%

Balance Sheet

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Total Assets	9.21B	10.76B	17.54B	19.31B	20.63B	22.58B	24.25B	25.49B	29.61B	32.83B
Total Liabilities	2.64B	3.86B	9.60B	9.94B	12.53B	13.47B	13.21B	11.96B	13.86B	14.47B
Total Equity	6.43B	6.77B	7.81B	9.22B	7.89B	8.49B	10.18B	12.53B	14.15B	16.07B
Cash	397.77M	1.27B	1.67B	2.33B	3.87B	2.44B	2.32B	5.65B	4.94B	4.49B
Net Debt	-	1.60B	4.47B	5.71B	6.09B	7.01B	6.74B	2.70B	5.32B	4.86B

Cash Flow

Currency: CNY	2016-12-31	2017-12-31	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31
Operating Cash Flow	592.03M	964.10M	1.05B	1.42B	1.03B	182.37M	1.65B	1.60B	167.76M	1.78B
Investing Cash Flow	-1.83B	-743.70M	-3.00B	-2.63B	138.20M	-3.44B	-	-	-	-
Financing Cash Flow	-	732.58M	2.40B	1.84B	253.98M	1.88B	-	-	-	-
Capital Expenditure	319.14M	507.32M	728.16M	999.34M	692.81M	556.20M	1.16B	1.17B	1.71B	1.00B
Free Cash Flow	-	338.92M	-1.44B	-1.48B	-486.43M	-1.36B	490.14M	430.23M	-1.54B	780.44M
Dividends Paid	106.98M	212.63M	289.72M	376.78M	175.49M	-	-	-	-	-
FCF to OCF	-	35.15%	-137.62%	-103.90%	-47.07%	-745.31%	29.64%	26.97%	-918.39%	43.77%
Dividend Paid to FCF	-	62.74%	-20.13%	-25.49%	-36.08%	-	-	-	-	-

Earnings

Report Date	Mar 25, 2027
EPS Estimate	-
EPS Actual	-
Surprise	-
Timing	After-hours

Key Statistics & Ratios

Market Cap818.95M

Enterprise Value976.50M

Trailing P/E20.20

Forward P/E18.35

Price / Sales0.13

Price / Book0.39

EPS0.01

Book Value0.52

Revenue (TTM)6.13B

Gross Profit (TTM)3.91B

EBITDA1.97B

Profit Margin11.36%

Operating Margin14.84%

Return on Equity4.27%

Return on Assets2.18%

Shares Outstanding3.99B

Shares Float2.20B

Beta0.87

Dividend Yield0.00%

Dividend Rate0.00

Payout Ratio0.00%

Dividends

20201×

0.01Jun 29, 2020

20192×

0.01Sep 9, 20190.01Jun 14, 2019

20183×

0.01Sep 6, 20180.01Jun 14, 20180.05Jun 13, 2018

20172×

0.00Oct 4, 20170.00Jun 15, 2017

20161×

0.00Oct 4, 2016